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Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44S34donor RTL remained a statistically signiﬁcant predictor for
recipient survival (HR¼0.63, 95% CI¼0.45-0.87, p¼0.006 for
longest tertile compared to the intermediate and shortest
tertiles)(ﬁg). There was no signiﬁcant interaction between
donor RTL and the patient’s underlying disease. Results were
similar when the analysis was limited to the severe aplastic
anemia group.
Conclusions: Our data suggest that longer donor telomere
lengths are signiﬁcantly associated with improved OS after
HCT for marrow failure syndromes, independent of donor
age. Additional studies of post-HCT donor telomere
dynamics are required to further explain this observation.17
Risk Factors for Graft Failure and Survival after Reduced
Intensity (RIC) Conditioning Allogeneic Hematopoietic
Cell Transplantation (HCT) for Myeloﬁbrosis
Brett Glotzbecker 1, Haesook T. Kim 2, Corey S. Cutler 3,
John Koreth 1, Philippe Armand 1, Sarah Nikiforow 3,
Joseph H. Antin 4, Robert J. Soiffer 3, Edwin P. Alyea III 1,
Vincent T. Ho 4. 1Dana-Farber Cancer Institute, Boston, MA;
2Biostatistics and Computational Biology, Dana-Farber Cancer
Institute, Boston, MA; 3Hematologic Malignancies, Dana-Farber
Cancer Institute, Boston, MA; 4Dana Farber Cancer Institute,
Boston, MA
Reduced intensity conditioning (RIC) HSCT is a potentially
curative therapy for Myeloﬁbrosis (MF), but graft failure is a
major cause of treatment failure. We evaluated the outcomes
and risk factors for graft failure and survival in patients un-
dergoing RIC HSCT. We performed a retrospective review of
all patients receiving a ﬁrst RIC HSCT for MF at Dana Farber
Cancer Institute/Brigham and Women’s Hospital between
January 1, 2000 and December 31, 2012. Primary graft failure
(PGF) was deﬁned as the inability to achieve an ANC greater
than 0.5x109/L for three consecutive days. Secondary failure
was deﬁned as achievement of WBC engraftment with sub-
sequent decline in chimerism to <50%, or need for donor
lymphocyte infusion (DLI) or second HSCT. An event was
deﬁned as primary or secondary graft failure or relapse.
Median age of the cohort (n¼ 40) was 62 years (44-73). The
RIC regimens included ﬂudarabine/IV busulfan 3.2 mg/kg
(Flu/Bu1) (24), ﬂudarabine/IV busulfan 6.4 mg/kg (Flu/Bu2)
(15), or ﬂudarabine/melphalan (1). A majority of patients
received tacrolimus, sirolimus and methotrexate (24) for
GVHD prophylaxis. Nine patients received ATG as part of the
conditioning. All received PBSC except one who received a
dUCBT. Thirty-four patients received 10/10 matched trans-
plants from related or unrelated donors. Eighteen patientsFigure 1.(45%) experienced graft failure including one patient with
PGF. 22.5% of all patients had D30 and 35% had D100
chimerism<50%. Unplanned DLI were needed in 12/40 (30%)
patients. Seven patients (17.5%) ultimately needed a second
transplant for persistent disease and/or poor chimerism.
Grade II-IV acute GVHD incidence at D180 was 18%. Chronic
GVHD incidence at 2 years was 27%. With median follow-up
of 28months, the 2-year EFS and OSwere 29% and 51%. Based
on univariate analysis, use of ATG (p¼0.03), female recipient
gender (p¼0.03), andWBC<5K at transplant (p¼0.016) were
associated with longer EFS, while predictors for superior OS
were absence of circulating blasts (p¼0.004), low platelet
count (p¼0.011) and unrelated donor (p¼0.03). DIPSS score
and spleen size did not predict for EFS or OS. There was a
trend toward improved 2-year OS in patients who received
Flu/Bu2 compared to those who received Flu/Bu1 (53% vs.
21%, p¼ 0.10). We developed a prognostic score based on
factors found to be signiﬁcant on univariate analysis. Based
on this composite score incorporating 1 point for platelet
count>100x109/L, blast count>5%, and non-MUD donor, the
2-year EFS was 49% for score<¼1 and 12% for score>¼2
(p¼0.0017); the 2-year OS was 67% for score<¼1 and 21% for
score>¼2 (p¼0.0003) (Figure 1). RIC HSCT using low dose
Flu/Bu is associated with a high incidence of mixed chime-
rism and late graft failure necessitating frequent unplanned
DLI or second HSCT. The incidence of graft failure may be
mitigated by increasing the intensity of the conditioning
regimen or addition of ATG.18
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Measurement of minimal residual disease (MRD) and the
analysis of chimerism after hematopoietic stem cell trans-
plantation (HSCT) have been used for the detection of
impending relapse. Here, we present the clinical relevance of
both methods. We investigated MRD in 135 consecutive
children with ALL (n¼62), AML (n¼42), MDS (n¼24), or CML
(n¼7) who underwent HSCT. The Wilms’ tumor gene (WT1)
expression was used for the detection of MRD because WT1
is overexpressed in the vast majority of patients with leu-
kemia. For the present study, we investigated if the MRD
status prior to HSCT has any prognostic value. We observed a
signiﬁcantly reduced cumulative incidence of relapse (7%
versus 48%; p<0.001) and a signiﬁcantly increased 5-year
event-free survival (84% versus 35%; p<0.001) in patients
who were MRD negative before transplantation. All 99 pa-
tients who were continuously MRD negative remained in
complete remission at a median of 2432 days after HSCT. In
contrast, all 34 patients who suffered from hematological
relapse after a median of 167 days presented with high levels
of WT1 gene expression (p<0.001). In 21 patients, we
observed an increase ofWT1 expression levels at a median of
31 days before hematological relapse. In 17 of these 21 pa-
tients, DNA was available at the time of increase of WT1
expression level to perform analysis of hematopoietic
chimerism using a quantitative short-tandem-repeat PCR.
Interestingly, only 9 of the 17 patients (53%) showed a mixed
chimerism, whereas 8 of the 17 patients (47%) revealed a
complete donor chimerism. In the remaining 13 patients
with relapse, no increase of WT1 expression levels could be
